Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation

Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the...

Full description

Saved in:
Bibliographic Details
Published inCrystEngComm Vol. 23; no. 3; pp. 653 - 662
Main Authors Jia, Jun-Long, Dai, Xia-Lin, Che, Hao-Jie, Li, Meng-Ting, Zhuang, Xiao-Mei, Lu, Tong-Bu, Chen, Jia-Mei
Format Journal Article
LanguageEnglish
Published Cambridge Royal Society of Chemistry 25.01.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid ( REG - MA ), glutaric acid ( REG - GA ) and pimelic acid ( REG - PA ) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H 2 O, REG - MA exhibits comparable dissolution behavior, while REG - GA and REG - PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG - GA and REG - PA have great potential to be developed as new, more efficient formulations of REG. Three cocrystals of regorafenib were synthesized, and two of them demonstrate significantly improved solubility and tabletability without compromising physicochemical stability.
AbstractList Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid ( REG – MA ), glutaric acid ( REG – GA ) and pimelic acid ( REG – PA ) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H 2 O, REG – MA exhibits comparable dissolution behavior, while REG – GA and REG – PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG – GA and REG – PA have great potential to be developed as new, more efficient formulations of REG.
Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H2O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid (REG–MA), glutaric acid (REG–GA) and pimelic acid (REG–PA) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H2O, REG–MA exhibits comparable dissolution behavior, while REG–GA and REG–PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG–GA and REG–PA have great potential to be developed as new, more efficient formulations of REG.
Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid ( REG - MA ), glutaric acid ( REG - GA ) and pimelic acid ( REG - PA ) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H 2 O, REG - MA exhibits comparable dissolution behavior, while REG - GA and REG - PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG - GA and REG - PA have great potential to be developed as new, more efficient formulations of REG. Three cocrystals of regorafenib were synthesized, and two of them demonstrate significantly improved solubility and tabletability without compromising physicochemical stability.
Author Li, Meng-Ting
Jia, Jun-Long
Dai, Xia-Lin
Che, Hao-Jie
Chen, Jia-Mei
Zhuang, Xiao-Mei
Lu, Tong-Bu
AuthorAffiliation School of Information Engineering
Tianjin Key Laboratory of Drug Targeting and Bioimaging
Institute for New Energy Materials and Low Carbon Technologies
School of Materials Science and Engineering
Tianjin University of Technology
Zhongshan Polytechnic
School of Chemistry and Chemical Engineering
AuthorAffiliation_xml – name: School of Information Engineering
– name: School of Chemistry and Chemical Engineering
– name: Zhongshan Polytechnic
– name: Institute for New Energy Materials and Low Carbon Technologies
– name: Tianjin University of Technology
– name: School of Materials Science and Engineering
– name: Tianjin Key Laboratory of Drug Targeting and Bioimaging
Author_xml – sequence: 1
  givenname: Jun-Long
  surname: Jia
  fullname: Jia, Jun-Long
– sequence: 2
  givenname: Xia-Lin
  surname: Dai
  fullname: Dai, Xia-Lin
– sequence: 3
  givenname: Hao-Jie
  surname: Che
  fullname: Che, Hao-Jie
– sequence: 4
  givenname: Meng-Ting
  surname: Li
  fullname: Li, Meng-Ting
– sequence: 5
  givenname: Xiao-Mei
  surname: Zhuang
  fullname: Zhuang, Xiao-Mei
– sequence: 6
  givenname: Tong-Bu
  surname: Lu
  fullname: Lu, Tong-Bu
– sequence: 7
  givenname: Jia-Mei
  surname: Chen
  fullname: Chen, Jia-Mei
BookMark eNptUd1LwzAQDzLBbfriuxDwTaxemrSkvmmdHzDwRZ_LNU1dRm1mkjnrX2-3iYr4dMfx-7j73YgMWttqQg4ZnDHg2XkFSgPjgpU7ZMhEmkYSOB_86vfIyPs5ABOMwZDUuVWu8wEbT21NnX62DmvdmpKuTJjRyih0pX3vGqMoKlP5C-q7Nsy0N_6Uqhk6VEE784HB2JZiW9GFswvtQkf1GzbLzXyf7Na9hT74qmPydDN5zO-i6cPtfX45jVTMeYhiiFGWDAQTSrA4yTBjEqTWVYJY8zTNMiUBVKV4ohnWUPJKoEw4CBHzhPExOd7q9ju8LrUPxdwuXdtbFrGQEGcAco062aKUs947XRcLZ17QdQWDYp1jcQ35ZJPjVQ-GP2Blwuao4NA0_1OOthTn1bf0z2v4J1EggYg
CitedBy_id crossref_primary_10_1039_D1CE01674A
crossref_primary_10_1016_j_colsurfa_2023_132835
crossref_primary_10_1016_j_drudis_2023_103527
crossref_primary_10_1016_j_heliyon_2024_e29049
crossref_primary_10_3390_pharmaceutics15092174
crossref_primary_10_3390_cryst12101337
crossref_primary_10_2174_1574892817666220913151252
crossref_primary_10_1016_j_jcou_2025_103040
crossref_primary_10_1021_acs_cgd_1c00480
crossref_primary_10_3390_pharmaceutics13060790
crossref_primary_10_1016_j_jddst_2023_105239
crossref_primary_10_3390_molecules28104242
Cites_doi 10.1021/acs.cgd.8b00362
10.1016/0006-291X(62)90292-9
10.1021/acs.molpharmaceut.5b00020
10.1016/j.phrs.2013.11.002
10.1021/mp5004652
10.3390/pharmaceutics12060546
10.1107/S2053229616003727
10.1016/j.molstruc.2008.01.009
10.1016/j.ejps.2015.10.006
10.1021/cg700843s
10.1021/acs.cgd.9b00618
10.1158/1078-0432.CCR-11-1900
10.1016/j.colsurfb.2017.02.006
10.1039/C8CE00341F
10.3390/71200871
10.1134/S0023158407030068
10.1021/acs.cgd.0c00326
10.1023/B:PHAM.0000016272.81390.b4
10.1021/jm070245n
10.1016/j.ijpharm.2006.07.016
10.1039/C5CC08216A
10.3390/cryst9120649
10.1007/s10953-009-9373-8
10.1002/ijc.25864
10.1039/D0CE00409J
10.1021/jm00129a030
10.1002/jps.2600590523
10.1517/13543784.2015.1070483
10.1517/17425247.2013.747508
10.1016/j.jddst.2019.101462
10.1039/C8CE00689J
10.1016/j.ijpharm.2012.10.043
10.1007/s11095-012-0709-5
10.1038/bjc.2012.153
ContentType Journal Article
Copyright Copyright Royal Society of Chemistry 2021
Copyright_xml – notice: Copyright Royal Society of Chemistry 2021
DBID AAYXX
CITATION
7U5
8FD
L7M
DOI 10.1039/d0ce01341b
DatabaseName CrossRef
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
DatabaseTitle CrossRef
Technology Research Database
Advanced Technologies Database with Aerospace
Solid State and Superconductivity Abstracts
DatabaseTitleList CrossRef
Technology Research Database

DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1466-8033
EndPage 662
ExternalDocumentID 10_1039_D0CE01341B
d0ce01341b
GroupedDBID 0-7
0R
1TJ
29F
5GY
70
705
70J
7~J
AAEMU
AAGNR
AAIWI
AANOJ
AAPBV
ABDVN
ABGFH
ABPTK
ABRYZ
ACGFS
ACLDK
ADACO
ADMRA
ADSRN
AENEX
AFVBQ
AGKEF
AGSTE
AGSWI
ALMA_UNASSIGNED_HOLDINGS
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CKLOX
CS3
E3Z
EBS
ECGLT
EE0
EF-
GNO
HZ
H~N
IDZ
J3I
JG
KC5
N9A
O9-
OK1
P2P
R7B
RCNCU
RIG
RNS
RPMJG
RRA
RRC
RSCEA
SKA
SLH
VH6
0R~
6J9
70~
AAJAE
AAMEH
AAWGC
AAXHV
AAXPP
AAYXX
ABASK
ABEMK
ABJNI
ABPDG
ABXOH
ACGFO
AEFDR
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRZK
AGEGJ
AGRSR
AHGCF
AKMSF
ANUXI
APEMP
CITATION
GGIMP
H13
HZ~
R56
RAOCF
7U5
8FD
L7M
ID FETCH-LOGICAL-c233t-202a8b10414c41259a91808eed5aaf36699c800cdc35e1af0b3d4a85304423513
ISSN 1466-8033
IngestDate Mon Jun 30 05:15:56 EDT 2025
Tue Jul 01 02:07:19 EDT 2025
Thu Apr 24 22:58:39 EDT 2025
Sat Jan 08 03:52:05 EST 2022
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c233t-202a8b10414c41259a91808eed5aaf36699c800cdc35e1af0b3d4a85304423513
Notes Electronic supplementary information (ESI) available. CCDC
For ESI and crystallographic data in CIF or other electronic format see DOI
2026456
10.1039/d0ce01341b
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ORCID 0000-0002-8605-6173
0000-0002-6087-4880
0000-0002-3959-901X
PQID 2480290081
PQPubID 2047491
PageCount 1
ParticipantIDs proquest_journals_2480290081
crossref_primary_10_1039_D0CE01341B
crossref_citationtrail_10_1039_D0CE01341B
rsc_primary_d0ce01341b
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210125
PublicationDateYYYYMMDD 2021-01-25
PublicationDate_xml – month: 1
  year: 2021
  text: 20210125
  day: 25
PublicationDecade 2020
PublicationPlace Cambridge
PublicationPlace_xml – name: Cambridge
PublicationTitle CrystEngComm
PublicationYear 2021
Publisher Royal Society of Chemistry
Publisher_xml – name: Royal Society of Chemistry
References Phan (D0CE01341B-(cit22)/*[position()=1]) 2019; 9
Thakur (D0CE01341B-(cit30)/*[position()=1]) 2009; 38
Tao (D0CE01341B-(cit33)/*[position()=1]) 2019; 19
Luo (D0CE01341B-(cit16)/*[position()=1]) 2018; 20
Sun (D0CE01341B-(cit40)/*[position()=1]) 2008; 8
Dai (D0CE01341B-(cit13)/*[position()=1]) 2020; 22
Shimpi (D0CE01341B-(cit21)/*[position()=1]) 2018; 18
Praphanwittaya (D0CE01341B-(cit9)/*[position()=1]) 2020; 55
Hu (D0CE01341B-(cit10)/*[position()=1]) 2017; 153
Eisenberg (D0CE01341B-(cit24)/*[position()=1]) 1962; 8
Wang (D0CE01341B-(cit14)/*[position()=1]) 2018; 20
Sun (D0CE01341B-(cit12)/*[position()=1]) 2013; 10
Das (D0CE01341B-(cit31)/*[position()=1]) 2007; 48
Dai (D0CE01341B-(cit37)/*[position()=1]) 2020; 20
Lin (D0CE01341B-(cit39)/*[position()=1]) 2016; 85
Sun (D0CE01341B-(cit26)/*[position()=1]) 2016; 72
Wilhelm (D0CE01341B-(cit1)/*[position()=1]) 2011; 129
Shiraishi (D0CE01341B-(cit25)/*[position()=1]) 1989; 32
Chow (D0CE01341B-(cit42)/*[position()=1]) 2012; 29
Abd El-Wahed (D0CE01341B-(cit32)/*[position()=1]) 2008; 888
Mross (D0CE01341B-(cit4)/*[position()=1]) 2012; 18
Thakuria (D0CE01341B-(cit19)/*[position()=1]) 2013; 453
Sun (D0CE01341B-(cit41)/*[position()=1]) 2006; 326
Sun (D0CE01341B-(cit17)/*[position()=1]) 2004; 21
Duggirala (D0CE01341B-(cit11)/*[position()=1]) 2016; 52
Lee (D0CE01341B-(cit2)/*[position()=1]) 2015; 24
Alfons (D0CE01341B-(cit6)/*[position()=1]) 2007
Pavlicic (D0CE01341B-(cit29)/*[position()=1]) 2002; 7
Juergen (D0CE01341B-(cit8)/*[position()=1]) 2007
Pinto (D0CE01341B-(cit28)/*[position()=1]) 2007; 50
Kale (D0CE01341B-(cit20)/*[position()=1]) 2020; 12
Sanphui (D0CE01341B-(cit18)/*[position()=1]) 2015; 12
Jr (D0CE01341B-(cit3)/*[position()=1]) 2014; 79
Surov (D0CE01341B-(cit15)/*[position()=1]) 2014; 11
Strumberg (D0CE01341B-(cit5)/*[position()=1]) 2012; 106
Fell (D0CE01341B-(cit27)/*[position()=1]) 1970; 59
References_xml – issn: 2007
  volume-title: Polymorph III of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
  doi: Alfons Juergen Katharina Birgit
– issn: 2007
  volume-title: Polymorph II of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
  doi: Juergen Alfons Katharina Birgit
– issn: 2007
  volume-title: 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
  doi: Alfons Juergen Katharina Birgit
– volume: 18
  start-page: 4378
  year: 2018
  ident: D0CE01341B-(cit21)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.8b00362
– volume: 8
  start-page: 437
  year: 1962
  ident: D0CE01341B-(cit24)/*[position()=1]
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/0006-291X(62)90292-9
– volume: 12
  start-page: 1615
  year: 2015
  ident: D0CE01341B-(cit18)/*[position()=1]
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/acs.molpharmaceut.5b00020
– volume: 79
  start-page: 34
  year: 2014
  ident: D0CE01341B-(cit3)/*[position()=1]
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2013.11.002
– volume: 11
  start-page: 3707
  year: 2014
  ident: D0CE01341B-(cit15)/*[position()=1]
  publication-title: Mol. Pharmaceutics
  doi: 10.1021/mp5004652
– volume: 12
  start-page: 156
  year: 2020
  ident: D0CE01341B-(cit20)/*[position()=1]
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12060546
– volume: 72
  start-page: 291
  year: 2016
  ident: D0CE01341B-(cit26)/*[position()=1]
  publication-title: Acta Crystallogr., Sect. C: Struct. Chem.
  doi: 10.1107/S2053229616003727
– volume: 888
  start-page: 416
  year: 2008
  ident: D0CE01341B-(cit32)/*[position()=1]
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2008.01.009
– volume: 85
  start-page: 141
  year: 2016
  ident: D0CE01341B-(cit39)/*[position()=1]
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2015.10.006
– year: 2007
  ident: D0CE01341B-(cit8)/*[position()=1]
– volume: 8
  start-page: 1575
  year: 2008
  ident: D0CE01341B-(cit40)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/cg700843s
– volume: 19
  start-page: 5636
  year: 2019
  ident: D0CE01341B-(cit33)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.9b00618
– volume: 18
  start-page: 2658
  year: 2012
  ident: D0CE01341B-(cit4)/*[position()=1]
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-1900
– volume: 153
  start-page: 61
  year: 2017
  ident: D0CE01341B-(cit10)/*[position()=1]
  publication-title: Colloids Surf., B
  doi: 10.1016/j.colsurfb.2017.02.006
– volume: 20
  start-page: 3025
  year: 2018
  ident: D0CE01341B-(cit16)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/C8CE00341F
– volume: 7
  start-page: 871
  year: 2002
  ident: D0CE01341B-(cit29)/*[position()=1]
  publication-title: Molecules
  doi: 10.3390/71200871
– volume: 48
  start-page: 381
  year: 2007
  ident: D0CE01341B-(cit31)/*[position()=1]
  publication-title: Kinet. Catal.
  doi: 10.1134/S0023158407030068
– volume: 20
  start-page: 5160
  year: 2020
  ident: D0CE01341B-(cit37)/*[position()=1]
  publication-title: Cryst. Growth Des.
  doi: 10.1021/acs.cgd.0c00326
– volume: 21
  start-page: 382
  year: 2004
  ident: D0CE01341B-(cit17)/*[position()=1]
  publication-title: Pharm. Res.
  doi: 10.1023/B:PHAM.0000016272.81390.b4
– volume: 50
  start-page: 5339
  year: 2007
  ident: D0CE01341B-(cit28)/*[position()=1]
  publication-title: J. Med. Chem.
  doi: 10.1021/jm070245n
– volume: 326
  start-page: 94
  year: 2006
  ident: D0CE01341B-(cit41)/*[position()=1]
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2006.07.016
– volume: 52
  start-page: 640
  year: 2016
  ident: D0CE01341B-(cit11)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C5CC08216A
– volume: 9
  start-page: 649
  year: 2019
  ident: D0CE01341B-(cit22)/*[position()=1]
  publication-title: Crystals
  doi: 10.3390/cryst9120649
– volume: 38
  start-page: 265
  year: 2009
  ident: D0CE01341B-(cit30)/*[position()=1]
  publication-title: J. Solution Chem.
  doi: 10.1007/s10953-009-9373-8
– volume: 129
  start-page: 245
  year: 2011
  ident: D0CE01341B-(cit1)/*[position()=1]
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.25864
– volume: 22
  start-page: 3670
  year: 2020
  ident: D0CE01341B-(cit13)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/D0CE00409J
– volume: 32
  start-page: 2214
  year: 1989
  ident: D0CE01341B-(cit25)/*[position()=1]
  publication-title: J. Med. Chem.
  doi: 10.1021/jm00129a030
– year: 2007
  ident: D0CE01341B-(cit6)/*[position()=1]
– volume: 59
  start-page: 688
  year: 1970
  ident: D0CE01341B-(cit27)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600590523
– volume: 24
  start-page: 1307
  year: 2015
  ident: D0CE01341B-(cit2)/*[position()=1]
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1517/13543784.2015.1070483
– volume: 10
  start-page: 201
  year: 2013
  ident: D0CE01341B-(cit12)/*[position()=1]
  publication-title: Expert Opin. Drug Delivery
  doi: 10.1517/17425247.2013.747508
– volume: 55
  start-page: 101462
  year: 2020
  ident: D0CE01341B-(cit9)/*[position()=1]
  publication-title: J. Drug Delivery Sci. Technol.
  doi: 10.1016/j.jddst.2019.101462
– volume: 20
  start-page: 5945
  year: 2018
  ident: D0CE01341B-(cit14)/*[position()=1]
  publication-title: CrystEngComm
  doi: 10.1039/C8CE00689J
– volume: 453
  start-page: 101
  year: 2013
  ident: D0CE01341B-(cit19)/*[position()=1]
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2012.10.043
– volume: 29
  start-page: 1854
  year: 2012
  ident: D0CE01341B-(cit42)/*[position()=1]
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-012-0709-5
– volume: 106
  start-page: 1722
  year: 2012
  ident: D0CE01341B-(cit5)/*[position()=1]
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2012.153
SSID ssj0014110
Score 2.3890772
Snippet Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced...
SourceID proquest
crossref
rsc
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 653
SubjectTerms Bioavailability
Cancer
Crystallography
Dicarboxylic acids
Dissolution
Dynamic stability
Fourier transforms
Hygroscopicity
Infrared analysis
NMR spectroscopy
Solubility
Thermal analysis
Title Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation
URI https://www.proquest.com/docview/2480290081
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELXo9gIHxFfF0oIswQWBwYmdbMKtpKlKFcolK-0tchynREJJtbuVuvx6xrETB6gQcIlW2XxInpfxG3vmDUKvQn8BrGEhyKLW24whlwRIbEyYimquIvi373X4-SI8W_LzVbByaUV9dcm2fCe_31pX8j9WhXNgV10l-w-WHR8KJ-A32BeOYGE4_pWNk06ud0DvjAJyX20iatU2pVle1Vsw67K72WkhayGbqk9_2-xaIH0boy0gR71mU45pdQO6Ky25O5ECn3LYRL8zbS91bcmYgHPdkmzI7m1GV79qBMmMSsGJaJy368h5o94kX13irWovSW77q2TNdC3C1wsRxNQt2yQmveIxpJv26SS2aZ2ZbYyL5aGWQDbyF4MPNjXHFmts4lBDIyVs5-bQeO7f3D5lWjW1olJRLVBXuslt2NC_-FKcLrOsyNNVvof2fQgq_BnaP07zT9m468SBCw0Stix-7573M2lxkcjeemgT09OR_AG6b-MIfGxA8RDdUe0jdG-iLvkY1Q4euKvxBB5YwwNP4YF7eHzAIzje4l-hgQEaeIAGdtB4gpanaZ6cEdtWg0ifsS18Qb6ISgjDPS458NtYxF5EIyBLgRA1C8M4lhBGyEqyQHmipiWruABaRzlw78BjB2jWdq16irAQolJlQP06UFx6LBKKciElp3HEFrKco9fDuBXSas7r1iffij73gcXFCU3Sfow_ztHL8doro7Ry61VHw_AX9kvcFD6PqB9rdjtHB2CS8X5nwWd_vu8Q3XV4PkKz7fpaPQe2uS1fWJD8ABjjhgk
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cocrystals+of+regorafenib+with+dicarboxylic+acids%3A+synthesis%2C+characterization+and+property+evaluation&rft.jtitle=CrystEngComm&rft.au=Jun-Long%2C+Jia&rft.au=Xia-Lin%2C+Dai&rft.au=Hao-Jie+Che&rft.au=Meng-Ting%2C+Li&rft.date=2021-01-25&rft.pub=Royal+Society+of+Chemistry&rft.eissn=1466-8033&rft.volume=23&rft.issue=3&rft.spage=653&rft.epage=662&rft_id=info:doi/10.1039%2Fd0ce01341b&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-8033&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-8033&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-8033&client=summon